Literature DB >> 23092776

Benign prostatic hyperplasia and lower urinary tract symptom guidelines.

Claus Roehrborn1.   

Abstract

Lower urinary tract symptoms (LUTS) are very common in men, with incidence increasing with age. Several clinical practice guidelines are available as decision-making aids for men with LUTS and the recommendations are based on the presumed etiology of the symptoms (due to obstruction, overactive bladder or a combination of the two). This review presents the various pharmacologic treatment options and summarizes key clinical trial data supporting their use.

Entities:  

Year:  2012        PMID： 23092776      PMCID： PMC3481951          DOI： 10.5489/cuaj.12231

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  12 in total

Review 1.  Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.

Authors:  Karl-Erik Andersson; William C de Groat; Kevin T McVary; Tom F Lue; Mario Maggi; Claus G Roehrborn; Jean Jacques Wyndaele; Thomas Melby; Lars Viktrup
Journal:  Neurourol Urodyn       Date:  2011-01-31       Impact factor: 2.696

2.  Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

Authors:  Russell Blair Egerdie; Stephen Auerbach; Claus G Roehrborn; Pierre Costa; Martin Sanchez Garza; Anne L Esler; David G Wong; Roberta J Secrest
Journal:  J Sex Med       Date:  2011-10-07       Impact factor: 3.802

3.  The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.

Authors:  Francesco Montorsi; Claus Roehrborn; Javier Garcia-Penit; Michael Borre; Ton A Roeleveld; Jean-Charles Alimi; Paul Gagnier; Timothy H Wilson
Journal:  BJU Int       Date:  2011-02-23       Impact factor: 5.588

4.  Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.

Authors:  Matthias Oelke; François Giuliano; Vincenzo Mirone; Lei Xu; David Cox; Lars Viktrup
Journal:  Eur Urol       Date:  2012-01-20       Impact factor: 20.096

5.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

6.  Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.

Authors:  Steven A Kaplan; John D McConnell; Claus G Roehrborn; Alan G Meehan; Michael W Lee; William R Noble; John W Kusek; Leroy M Nyberg
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

7.  Evaluation and treatment of lower urinary tract symptoms in older men.

Authors:  P Abrams; C Chapple; S Khoury; C Roehrborn; J de la Rosette
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

8.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.

Authors:  Ji Youl Lee; Hyun Woo Kim; Seung Ju Lee; Jun Sung Koh; Hong Jin Suh; Michael B Chancellor
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

9.  Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.

Authors:  Paul Abrams; Steven Kaplan; Hendrik J De Koning Gans; Richard Millard
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

10.  Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

Authors:  Claus G Roehrborn; Kevin T McVary; Albert Elion-Mboussa; Lars Viktrup
Journal:  J Urol       Date:  2008-08-22       Impact factor: 7.450
View more
  3 in total

Review 1.  A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms.

Authors:  Michael Erlano Chua; Jonathan Mendoza; Manuel See; Ednalyn Esmena; Dean Aguila; Jan Michael Silangcruz; Buenaventura Jose Reyes; Saturnino Luna; Marcelino Morales
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 2.  Research Findings on Overactive Bladder.

Authors:  Phani B Patra; Sayani Patra
Journal:  Curr Urol       Date:  2015-05-20

3.  Shrinkage of Prostate and Improved Quality of Life: Management of BPH Patients with Croton membranaceus Ethanolic Root Extract.

Authors:  George Awuku Asare; Daniel Afriyie; Robert A Ngala; Alfred A Appiah; Yvonne Anang; Iddi Musah; Samuel Adjei; Kwabena Bamfo-Quaicoe; Derick Sule; Ben A Gyan; Peter Arhin; Dominic A Edoh
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-02       Impact factor: 2.629
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.